Search research articles
Contact Us
Filters
Showing results (11-20 of 41) with videos related to
Page
of 5
Sort By:
Cancer Causes & Control : CCC
|
April 19, 2025
de novo metastases in patients with primary colorectal cancer: a Surveillance, Epidemiology, and End Results analysis
Nicole C Loroña, Kamya Sankar, Mariana C Stern, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
March 5, 2014
In vitro analysis of RNA degradation catalyzed by deadenylase enzymes
Joel Hrit, Nathan Raynard, Jamie Van Etten, et al.
Advances in Therapy
|
November 12, 2025
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Kamya Sankar, Sudhir Unni, Marian Eberl, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 4, 2022
Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer
Alex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 22, 2022
Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab
Alex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
International Journal of Molecular Sciences
|
April 28, 2023
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
Jun Ho Ji, Sang Yun Ha, Danbi Lee, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 13, 2021
Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer
Alex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
Cancers
|
February 15, 2022
Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer
Kamya Sankar, Alex K Bryant, Garth W Strohbehn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2022
De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer
Alex K Bryant, Kamya Sankar, Lili Zhao, et al.
Translational Gastroenterology and Hepatology
|
August 21, 2023
Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers
Kamya Sankar, Ashley N Pearson, Tejaswi Worlikar, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 41) with videos related to
Sort By:
Page
of 5
Cancer Causes & Control : CCC
|
April 19, 2025
de novo metastases in patients with primary colorectal cancer: a Surveillance, Epidemiology, and End Results analysis
Nicole C Loroña, Kamya Sankar, Mariana C Stern, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
March 5, 2014
In vitro analysis of RNA degradation catalyzed by deadenylase enzymes
Joel Hrit, Nathan Raynard, Jamie Van Etten, et al.
Advances in Therapy
|
November 12, 2025
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Kamya Sankar, Sudhir Unni, Marian Eberl, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 4, 2022
Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer
Alex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 22, 2022
Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab
Alex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
International Journal of Molecular Sciences
|
April 28, 2023
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
Jun Ho Ji, Sang Yun Ha, Danbi Lee, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 13, 2021
Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer
Alex K Bryant, Kamya Sankar, Garth W Strohbehn, et al.
Cancers
|
February 15, 2022
Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer
Kamya Sankar, Alex K Bryant, Garth W Strohbehn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2022
De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer
Alex K Bryant, Kamya Sankar, Lili Zhao, et al.
Translational Gastroenterology and Hepatology
|
August 21, 2023
Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers
Kamya Sankar, Ashley N Pearson, Tejaswi Worlikar, et al.
Page
of 5